US regulatory status: approved. Molecular target: Prostaglandin E2 receptor EP1 subtype.
- Target
- Prostaglandin E2 receptor EP1 subtype
- Mechanism
- Prostanoid EP1 receptor agonist
pharma · Geographic Atrophy · Geographic Atrophy Secondary to Age-related Macular Degeneration · APLS
Genzyme Europe
Apellis Europe B.V.
Genzyme Europe drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Gooimeer 10, Naarden, None 1411 DD, NL, WALTHAM, MA HQ
1981 Founded
273 Employees
Public company Type
APLS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Gooimeer 10, Naarden, None 1411 DD, NL, WALTHAM, MA
- Founded
- 1981
- Employees
- 273
- Programs
- 20
- Drugs
- 5
- Patents
- 24
Genzyme Europe pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Genzyme Europe drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Genzyme Europe's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
pegcetacoplan
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Complement C3.
- Target
- Complement C3
- Mechanism
- Complement C3 inhibitor